Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention

Summary There is increasing appreciation that complement dysregulation lies at the heart of numerous immune‐mediated and inflammatory disorders. Complement inhibitors are therefore being evaluated as new therapeutic options in various clinical translation programs and the first clinically approved c...

Full description

Saved in:
Bibliographic Details
Published in:Molecular oral microbiology 2016-02, Vol.31 (1), p.3-17
Main Authors: Mastellos, D.C., Ricklin, D., Hajishengallis, E., Hajishengallis, G., Lambris, J.D.
Format: Article
Language:English
Subjects:
Animals
complement
Complement C3 - antagonists & inhibitors
Complement C3 - immunology
Complement Inactivating Agents - pharmacology
compstatin Cp40
Dentistry
Humans
inflammation
Inflammation - drug therapy
Inflammation - immunology
inflammation, periodontitis
Inflammatory diseases
Molecular Targeted Therapy
periodontitis
Periodontitis - drug therapy
Periodontitis - immunology
Pharmaceutical industry
primate models
therapeutics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary There is increasing appreciation that complement dysregulation lies at the heart of numerous immune‐mediated and inflammatory disorders. Complement inhibitors are therefore being evaluated as new therapeutic options in various clinical translation programs and the first clinically approved complement‐targeted drugs have profoundly impacted the management of certain complement‐mediated diseases. Among the many members of the intricate protein network of complement, the central component C3 represents a ‘hot‐spot’ for complement‐targeted therapeutic intervention. C3 modulates both innate and adaptive immune responses and is linked to diverse immunomodulatory systems and biological processes that affect human pathophysiology. Compelling evidence from preclinical disease models has shown that C3 interception may offer multiple benefits over existing therapies or even reveal novel therapeutic avenues in disorders that are not commonly regarded as complement‐driven, such as periodontal disease. Using the clinically developed compstatin family of C3 inhibitors and periodontitis as illustrative examples, this review highlights emerging therapeutic concepts and developments in the design of C3‐targeted drug candidates as novel immunotherapeutics for oral and systemic inflammatory diseases.
ISSN:2041-1006
2041-1014
DOI:10.1111/omi.12129